After rereading the Sembiosys PR several times, it strikes me as unusual and perhaps it underscores some irony in SBS' apparent success.
The PR, IMO , comes off sounding like a weak attempt to draw attention to itself, with nothing new to say.
I would just add that it strikes me as a desperate plea to MDCO for MDCO to partner with them to provide necessary validation of their technology and, more importantly, much needed capital. They effectively come right out in the PR and say that they can help MDCO get to where they need to in producing their ApoA1, in addition to having the ability to manufacture their own ApoA1. Whether MDCO believes that to be true and that it needs such assistance from Sembiosys is of course another story.
So what's the problem and why is the stock down 90% over past 2 yrs? Despite their success at producing literally tons of commercial grade product, they don't have a route to market, they don't have a partner, and, now I gather, they don't own the intellectual property to develop apo A-1. So, it seems to me that the fate and the value of the company lies in the hands of MDCO. It could still be a home-run, but if they felt secure, I don't think they would be issuing a PR like that.
I'm not sure where you get that Sembiosys doesn't have the intellectual property to develop ApoA1. I would imagine they do have the necessary IP backing their own production methods of ApoA1 (they obviously don't have MDCO's patents); the big question is whether or not MDCO (or others) believes they need to utilize Sembiosys' manufacturing methods or if they can resolve the manufacturing issues on their own or by utilizing some other third party. Sembiosys could be a home-run of course if MDCO or some other party does partner with them, but the company hasn't provided any evidence in the past of being able to land a lucrative partnership so I'm not sure that's a bet I want to take.
Market Data 
Markets 
AI
